Table 2.

Comparison of Growth Responses Between Long-Acting and Daily Growth Hormones in Pediatric Growth Hormone Deficiency.16,24,29

	lonapegsomatropin (Phase 3)	Somatrogon (Phase 3)	Somapacitan (Phase 2)
Mechanism	Reversible PEGylation	Fusion Protein with hCG CTP (x3)	Acylation increases binding to Albumin
Molecular weight of the active agent (kDa)	22	41	23.3
Dose (mg/kg/wk)	0.24	0.66	0.16
Height velocity LAGH (cm/yr)	11.2	10.1	11.5
Height velocity DGH (cm/yr)	10.3	9.8	10.5
Estimated average IGF-1 SDS on LAGH	+0.72	Data not available	+0.31

Notes: Height velocity data from Phase 2 (Somapacitan) and Phase 3 (Lonapegsomatropin and Somatrogon). The DGH dose was 0.034 mg/kg/day (0.24 mg/kg/wk) in each study. Estimated average IGF-1 SDS was based upon LAGH product specific pharmacokinetic modeling.

Abbreviations: cm, centimeter; CTP, C-terminal peptide; DGH, daily growth hormone; hCG, human chorionic gonadotropin; IGF-I, insulin-like growth factor I; kDa, kilodalton; kg, kilogram; mg, milligram; SDS, standard deviation score; wk, week; yr, year.